Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 26, 2025	Sep. 27, 2024	Sep. 26, 2025	Sep. 27, 2024
Net sales	$ 753.1	$ 505.5	$ 1,658.1	$ 1,487.6
Cost of sales	499.1	284.4	969.4	907.5
Gross profit	254.0	221.1	688.7	580.1
Selling, general and administrative expenses	351.7	141.2	649.8	406.0
Combination, integration, and other related expenses		0.0	136.9	0.0
Research and development expenses	44.3	28.2	88.4	85.3
Restructuring charges, net	0.0	0.1	(2.2)	10.5
Liabilities management and separation costs	33.3	15.2	36.9	32.2
Operating (loss) income	(269.1)	36.4	(221.1)	46.1
Interest expense	(70.6)	(59.0)	(136.0)	(177.5)
Interest income	(6.5)	(7.4)	(18.2)	(20.2)
Gain on debt extinguishment	4.6	0.0	4.6	0.0
Gain on divestiture	0.8	0.0	(5.9)	0.0
Other income (expense), net	0.8	(3.8)	2.2	(3.6)
Loss from continuing operations before income taxes	(327.0)	(19.0)	(338.0)	(114.8)
Income tax (benefit) expense	(35.9)	7.2	(21.3)	20.4
Loss from continuing operations	(291.1)	(26.2)	(316.7)	(135.2)
Income from discontinued operations, net of income taxes	0.0	0.0	0.3	0.3
Net loss	$ (291.1)	$ (26.2)	$ (316.4)	$ (134.9)
Basic (loss) income per share (Note 7):
Loss from continuing operations (in dollars per share)	$ (9.01)	$ (1.33)	$ (13.25)	$ (6.86)
Income from discontinued operations (in dollars per share)	0	0	0.01	0.02
Net loss (in dollars per share)	$ (9.01)	$ (1.33)	$ (13.24)	$ (6.85)
Basic weighted-averaged shares outstanding (in shares)	32.3	19.7	23.9	19.7
Diluted (loss) income per share (Note 7):
Loss from continuing operations (in dollars per share)	$ (9.01)	$ (1.33)	$ (13.25)	$ (6.86)
Income from discontinued operations (in dollars per share)	0	0	0.01	0.02
Net loss (in dollars per share)	$ (9.01)	$ (1.33)	$ (13.24)	$ (6.85)
Diluted weighted-average shares outstanding (in shares)	32.3	19.7	23.9	19.7
Mallinckrodt & Endo Merger
Combination, integration, and other related expenses	$ 93.8		$ 136.9